Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta)

Indian Journal of Medical Research

Volumn 137, Issue 6, 2013, Pages 1072-1088

  Dinesh Kumar, B ^a   Uday Kumar, P ^a   Prasanna Krishna, T ^a   Kalyanasundaram, S ^a   Suresh, P ^a   Jagadeesan, V ^a   Hariharan, S ^a   Nadamuni Naidu, A ^a   Krishnaswamy, Kamala ^a   Rangarajan, P N ^b   Srinivasan, V A ^c   Reddy, G S ^c   Sesikeran, B ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c Indian Immunologicals Limited   (India)

Author keywords

Biotech products; Combination rabies vaccine (CRV); DNA rabies vaccine (DRV); Pre clinical toxicology; Purified vero cell derived inactivated rabies virus vaccine; PVRV; Safety evaluation; Toxicology

Indexed keywords

RABIES VACCINE; RECOMBINANT VACCINE; TIABENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BEHAVIOR; BLOOD ANALYSIS; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MEGADOSE; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOPATHOLOGY; IMMUNOTOXICITY; MALE; NEUROLOGIC EXAMINATION; NONHUMAN; PARAMETERS; POLYMERASE CHAIN REACTION; RABIES; RHESUS MONKEY; SINGLE DRUG DOSE; THORAX RADIOGRAPHY; TOXICITY TESTING;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; FEMALE; HUMANS; MACACA MULATTA; MALE; RABIES; RABIES VACCINES; RABIES VIRUS; TOXICITY TESTS; VACCINES, COMBINED; VACCINES, DNA; VERO CELLS;

EID: 84879520999     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Klinman DM, Klaschik S, Trossa D, Shirota H, Steinhagen F. FDA guidance on prophylactic DNA vaccines: Analysis and recommendations. Vaccine 2010; 28: 2801-5.
2. Daniela F, Sandra I, VitoMichele F, Monica R. DNA Vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010: 174378.
3. Brennan FR, Dougan G. Non-clinical safety evaluation of noval vaccines and adjuvants: new products, new strategies. Vaccine 2005; 23: 3210-22.
4. Tullu MS, Rodrigues S, Muranjan MN, Bavdekar SB, Kamat JR, Hira PR. Neurological complications of rabies vaccines. Indian Pediatr 2003; 40: 50-4.
5. Lodmell DL, Ray NB, Parnell MJ, Ewalt LC, Hanlon CA, Shaddock JH, et al. DNA immunization protects nonhuman primates against rabies virus. Nat Med 1998; 4: 949-52.
6. Biswas S, Ashok MS, Reddy GS, Srinivasan VA, Rangarajan PN. Evaluation of the protective efficacy of a rabies DNA vaccine in mice using intracerebral challenge model. Curr Sci 1999; 76: 1012-6.
7. Biswas S, Kalanidhi AP, Ashok MS, Raddy GS, Srinivasan VA, Rangarajan PN. Evaluation of rabies virus neutralizing antibody titres induced by intramuscular inoculation of rabies DNA vaccine in mice and Bonnet monkeys. Indian J Exp Biol 2001; 39: 533-6.
8. Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN. Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 2001; 12: 1917-22.
9. Uday Kumar P, Dinesh Kumar B, Annapurna VV, Prasanna Krishna T, Kalyanasundaram S, Suresh P, et al. Nonclinical toxicology study of recombinant-plasmid DNA anti-rabies vaccines. Vaccine 2006; 24: 2790-8.
10. Sistare FD, DeGeorge JJ. Pre-clinical predictors of clinical safety: opportunities for improvement. Clin Pharmacol Ther 2007; 82: 210-4.
11. FDA(2007): Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. Available from: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm074770.htm, accessed on December 12, 2001.
12. International Council for Standardization in Haematology Expert Panel on Blood Rheology. ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993; 46: 198-203.
13. Drugs and Cosmetics (Iind Amendment) Rules, 2005 "Schedule Y [See Rules 122a, 122b, 122d, 122da, 122daa and 122e]. Available from: http://dbtbiosafety.nic.in/act/ schedule_y.pdf accessed on February 15, 2006.
14. FDA (1997a): Guidelines for industry and reviews repeal of section 507 of Federal Food, Drug and Cosmetic Act, USA. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm078754.pdf accessed on December 17, 2001.
15. FDA. (1997b): Points to consider in the manufacturing and testing of monoclonal antibody; products for human use. Federal Food, Drug and Cosmetic Act, USA. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ OtherRecommendationsforManufacturersUCM153306.pdf, accessed on January 15, 2002.
16. Weissnger J. Preclinical pharmacology and toxicology of haemopoitic factors. BiotechnolAdv 1989; 7: 387-99.
17. Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007; 6: 120-6.
18. Gephart LA, Salminen WF, Nicolich MJ, Pelekis M. Evaluation of subchronic toxicity data using the benchmark dose approach. Regul Toxicol Pharmacol 2001; 33: 37-59.
19. Sethi N, Singh RK, Srivastava RK. Subacute toxicity of adsorbed 250 Lf tetanus toxoid in rats. Indian J Exp Biol 1990; 28: 218-20.
20. Petricciani JC. Recombinant DNA vaccines and therapeutics. Lancet 1993; 342: 1067-8.
21. Warner GL, Haggerty HG. In: Sipes IG, MC Queen CA, Gandolfi AJ, editors. Immunotoxicology of recombinant DNA derived therapeutic proteins in comprehensive toxicology. USA: Pergamon Press; 2001. p. 435-50.
22. Sheets RL, Stein J, Manetz TS. Biodistribution ofDNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or west nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006; 91: 610-9.
23. Lin K, Roosinovich E, Barbara M, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol Res 2010; 47: 86-112.